Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Letter Dermatology

A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab

Ying Shan et al.

DERMATOLOGIC THERAPY (2022)

Article Dermatology

Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines

Saori Takamura et al.

Summary: Investigated the dynamics of cytokine-producing T cells before and after treatment in a patient with bullous pemphigoid (BP), and found that Th2 cells are involved in the pathogenesis of BP, and dupilumab exerts its effect mainly by suppressing Th2 cytokines.

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients

Xiuting Liu et al.

EUROPEAN JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Immunology

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

S. Morteza Seyed Jafari et al.

Summary: Combination therapy with omalizumab and dupilumab showed a complete response in a patient with refractory BP, offering a potential treatment option for similar cases.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Yihua Zhang et al.

Summary: In the treatment of Bullous Pemphigoid (BP), dupilumab in combination with methylprednisolone and azathioprine appears to be superior to methylprednisolone/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article